Trastuzumab News and Research

RSS

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomized phase III study reported at the ESMO Asia 2019 Congress.

22 Nov 2019

Promising method to identify aggressive breast cancers that will respond to immunotherapy

University of North Carolina Lineberger Comprehensive Cancer Center researchers have discovered a promising method to identify aggressive breast cancer tumors that will respond to drugs that unleash the immune system against cancer.

14 Nov 2019

Key metabolic changes found in patients with chemotherapy-related heart toxicity

More and more patients are being treated successfully for cancer. However, some cancer treatments that are very effective for breast cancer – medications like anthracyclines and trastuzumab – can cause heart dysfunction and lead to heart failure.

19 Jul 2019

New research shows significant gaps in deployment of 'coverage with evidence development'

Value in Health, the official journal of ISPOR- the professional society for health economics and outcomes research, announced today the publication of new research from The Netherlands showing important gaps in the deployment of "coverage with evidence development," a type of pharmaceutical managed entry agreement that gives patients access to treatments while additional evidence is being collected.

15 Jul 2019

Researchers develop DNA nanorobots that target breast cancer cells

According to the Mayo Clinic, about 20% of breast cancers make abnormally high levels of a protein called human epidermal growth factor receptor 2 (HER2).

17 Jun 2019

Medication could mitigate side effects of chemotherapy for breast cancer patients

Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug.

14 Mar 2019

CT scans used in cancer diagnostics can provide valuable clues to preventing heart problems

An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's risk for heart problems in the months and years after treatment.

7 Mar 2019

New identified biomarker predicts patients who might benefit from HER2-targeted agents

In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.

22 Feb 2019

Study shows precision medicines could aid more breast cancer patients via RNA-targeting

When women or men receive the worrisome diagnosis of breast cancer, that news comes with an important piece of information, namely, whether their cancer is HER2-positive or HER2-negative.

8 Feb 2019

New substance could improve efficacy of established breast cancer treatments

Physicians from Karl Landsteiner University of Health Sciences in Krems (Austria) demonstrate potential for clinical application, collaborating with research groups from Germany, the USA, and China.

13 Dec 2018

Cancer patients who take beta-blocker along with breast cancer drug have less heart damage

Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented today at EuroEcho-Imaging 2018.

5 Dec 2018

Two genomic tests help identify most effective treatment for breast cancer patients

New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalized medicine ever nearer.

14 Nov 2018

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.

14 Nov 2018

New study shows promise of innovative strategy against HER2-driven lung cancers

The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients per year.

8 Nov 2018

$Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer$

Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy.

22 Oct 2018

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

12 Oct 2018

Researchers discover potential new approach to block growth of HER2 positive breast cancer

Researchers at Mayo Clinic have identified an important new pathway by which HER2 positive breast cancers grow and have discovered that a dietary supplement called cyclocreatine may block the growth of HER2 positive breast cancer.

30 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

Clinical trial results of tucatinib with T-DM1 shows promise in treating HER2+ breast cancer

Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib with T-DM1 against heavily pretreated HER2-positive breast cancer.

11 Jul 2018